CohBar

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief Scientific Officer, Dr. Kenneth Cundy, will participate on the panel titled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus” at the ROTH Capital COVID-19 Therapeutics in Development Event, being held virtually on October 28, 2020 at 7:30am PT. A live webcast of the presentation will be available for attendees who register at https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ.

CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, November 6 at 2:00pm ET Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, November 6 at 2:00pm ET

CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the BIO-Europe Conference, being held virtually on October 26 - 29, 2020. This presentation will be available on demand for BIO-Europe attendees.

CohBar to Present at the BIO-Europe Conference

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020. A live webcast of the presentation will be available for attendees who register at http://www.metabesity2020.com/register.html. Viewing is complimentary.

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.

CohBar to Present at the BIO Investor Forum

MENLO PARK, Calif., Sept.  29, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright 4th Annual NASH Investor Conference, being held virtually on October 5, 2020.

CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

MENLO PARK, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit, being held virtually on September 21-23, 2020.

CohBar to Present at the Oppenheimer Fall  Healthcare, Life Sciences, & MedTech Summit

MENLO PARK, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

MENLO PARK, Calif., Aug.  28, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the closing of its previously announced underwritten public offering of 12,300,000 units at a price to the public of $1.22 per unit.  Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of a share of common stock at a per share exercise price of $1.44. In addition, the underwriters partially exercised the over-allotment option for warrants to purchase an additional 1,383,750 shares. The warrants are exercisable for five years from the closing date of the offering. The aggregate gross proceeds from this offering were approximately $15.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

CohBar Announces Closing of Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug.  24, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the first subjects have been dosed with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for NASH and obesity. The Phase 1b study is a double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in twenty obese subjects with NAFLD. This study is designed to assess the potential effects of CB4211 on liver fat, body weight, and various biomarkers that are relevant to NASH, obesity and metabolic disease. Subjects are required to have a minimum of 10% liver fat at enrollment, and to stay in the clinical study unit during the four weeks of treatment. The study resumed in July after a pause in March due to the COVID-19 pandemic.

CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc. (CWBR) CEO Steve Engle on Q2 2020 Results - Earnings Call Transcript

New positive preliminary preclinical results in ARDS model  Company to host conference call and webcast at 5:00 p.m. ET

CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update

In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF) In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF)

CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020

MENLO PARK, Calif., July  07, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it has resumed the Phase 1b stage of its Phase 1a/1b clinical trial of CB4211, its lead candidate for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. In March 2019, the company announced the temporary pause of the clinical study in response to the COVID-19 pandemic.

CohBar Resumes CB4211 Phase 1b Clinical Trial

MENLO PARK, Calif., July  06, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Sachs Novel Coronavirus Investment Forum, being held July 7-9, 2020 with a focus on its CB5064 analogs targeting the coronavirus disease 2019 (COVID-19) associated ARDS.

CohBar to Present at Sachs Novel Coronavirus Investment Forum

MENLO PARK, Calif., June  30, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, was added to the US small-cap Russell 2000® Index during the 2020 Russell Indexes reconstitution, effective after the US market close on June 26th. Membership in the Russell 2000® Index, which remains in place for at least one year, is based on membership in the broad-market Russell 3000® Index. The company also sold shares of common stock through its previously disclosed ATM offering with net proceeds of approximately $4.4M in funding through the June 26th reconstitution.

CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering

MENLO PARK, Calif., June  02, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, is hosting its Annual Shareholder Meeting and Investor Update on June 16, 2020. 

CohBar to Hold 2020 Annual Shareholder Meeting and Investor Update June 16, 2020

CohBar, Inc. (CWBR) CEO Steve Engle on Q1 2020 Results - Earnings Call Transcript

Former senior executive to continue on CohBar Board of Directors Former senior executive to continue on CohBar Board of Directors

CohBar’s Chief Operating Officer Jon Stern Plans to Step Down from Management Role

CohBar Looks Undervalued Ahead Of Upcoming Data Readout

Preclinical Testing of CB5064 Analogs Initiated in ARDS Preclinical Testing of CB5064 Analogs Initiated in ARDS

CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides

MENLO PARK, Calif., May  01, 2020  (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the  American Thoracic Society (ATS) 2020 International Conference was published in today’s edition of the American Journal of Respiratory and Critical Care Medicine. CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).

CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

COVID-19 Pandemic Impact at Clinical Sites Delays Study COVID-19 Pandemic Impact at Clinical Sites Delays Study

CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript

News for CohBar Stock (CWBR)